4SC expands domatinostat combo testing

The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.

Read more

Cell transdifferentiation specialist Mogrify Ltd raises US$16m

British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.

Read more

Patient’s organoids predict response to chemotherapy

A new test based on tumour organoids can predict how patients with advanced colorectal cancer (CRC) respond to chemotherapy treatment.

Read more

Novo Nordisk enters hemophilia gene therapy field

Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies Novo Nordisk A/S tries to get foothold in the emerging hemophilia A gene therapy market.

Read more

Researchers unravel how ADEP antibiotics work

German researchers have unraveled the mechanism of a ADEPs, a novel class of antibiotics, allowing pharmacological optimisation.

Read more

New method allows tracking of HIV

A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.

Read more

Rottapharm Biotech: POC in osteoarthritis pain

Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.

Read more

Creoptix AG closes CHF8m financing round

Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.

Read more